Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 8/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 7/20 | 0.38 |
| ▸ | MAOB | P27338 | 6/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30182887 | 1.00 | SLC6A2 (0.57) | SLC6A2SLC6A3SLC6A4HRH1KDM1A | |
| SCHEMBL15574817 | 0.85 | SLC6A2 (0.52) | SLC6A2SLC6A3SLC6A4HRH1KDM1A | |
| SCHEMBL15574816 | 0.85 | SLC6A2 (0.52) | SLC6A2SLC6A3SLC6A4HRH1KDM1A | |
| SCHEMBL15574815 | 0.85 | SLC6A2 (0.52) | SLC6A2SLC6A3SLC6A4HRH1KDM1A | |
| SCHEMBL28402743 | 0.84 | SLC6A2 (0.45) | SLC6A2SLC6A3SLC6A4HRH1KDM1A | |
| SCHEMBL25741447 | 0.82 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4HRH1KDM1A | |
| SCHEMBL7845951 | 0.82 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4HRH1KDM1A | |
| SCHEMBL30212387 | 0.80 | KMT2A (0.47) | SLC6A2SLC6A3SLC6A4CYP1A2CYP3A4 | |
| SCHEMBL2647849 | 0.80 | HRH1 (0.59) | SLC6A2SLC6A3SLC6A4HRH1KDM1A | |
| SCHEMBL2647851 | 0.80 | HRH1 (0.59) | SLC6A2SLC6A3SLC6A4HRH1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4580405-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | Oerth Bio LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050016-A9 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20240365736-A1 | COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL | OERTH BIO LLC (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4370512-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | Cytokinetics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024050016-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2023288195-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210171470-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-02-11 | — | — | US | disclosed |
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-01-14 | — | — | US | disclosed |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | SLC6A2 4074/4885SLC6A3 3103/4885SLC6A4 2864/4885 |
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | SLC6A2 4068/4885SLC6A3 3083/4885SLC6A4 2849/4885 |
| US-20210171470-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | SLC6A2 4068/4885SLC6A3 3083/4885SLC6A4 2849/4885 |
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | SLC6A2 4074/4885SLC6A3 3103/4885SLC6A4 2864/4885 |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | SLC6A2 4068/4885SLC6A3 3083/4885SLC6A4 2849/4885 |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | SLC6A2 4068/4885SLC6A3 3083/4885SLC6A4 2849/4885 |
| US-20240365736-A1 | COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL | CRBN, LTN1, CBL | SLC6A2 4834/4885SLC6A3 4813/4885SLC6A4 4818/4885 |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | SLC6A2 1106/4885SLC6A3 483/4885SLC6A4 1596/4885 |
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | SLC6A2 4074/4885SLC6A3 3103/4885SLC6A4 2864/4885 |
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | CRBN, STUB1, CUL1 | SLC6A2 4725/4885SLC6A3 4365/4885SLC6A4 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.